Health Canada’s investment through its Organ Donation and Transplantation Collaborative, whose mandate is to help make transformative changes in organ donation and transplantation systems across Canada, has awarded $1.1 million to Nova Scotia Health, in collaboration with its key partners including: Nova Scotia Department of Health and Wellness, Canadian Donation and Transplant Research Program, Transplant Québec, and Canadian Blood Services. The purpose of the study is to gather evidence to inform legislative strategies to improve donation and to rigorously evaluate the impact of the overall implementation.
CO-VIC, the COVID-19 treatment and immunity study, will evaluate effectiveness of treatments for hospitalized patients suffering moderate to severe COVID-19 symptoms, while helping researchers discover more about immunity to the virus.
Researchers at NSHA who played a key role in getting a new drug approved in Canada for polycystic kidney disease are taking part in a national follow-up study of the drug’s long-term effects.
While the number of patients waiting for a kidney transplant has risen by 400 per cent over the past 25 years, the number of kidney donors has risen by only four per cent.
At any given time, the Division of Nephrology is involved in half a dozen clinical trials to test and/or validate new approaches to managing the many issues that arise with dialysis and kidney disease.
Although colon cancer is not in the spotlight like breast and prostate cancer, it is the second-most common cancer in Nova Scotia in both women and men. And, rates are higher in Atlantic Canada than the rest of the country.
If fatty liver disease is diagnosed early enough—before it progresses to the inflammatory stage that accelerates scarring and leads to cirrhosis—it can be halted and even reversed with weight loss and lifestyle changes.
